{"id":2858,"date":"2019-10-08T21:57:12","date_gmt":"2019-10-08T19:57:12","guid":{"rendered":"https:\/\/idibell.cat\/?page_id=2858"},"modified":"2024-04-17T08:57:36","modified_gmt":"2024-04-17T06:57:36","slug":"clinical-prevention","status":"publish","type":"page","link":"https:\/\/idibell.cat\/en\/research\/translational-medicine-area\/digestive-system-diagnostics-pharmacogenetics-care-support-and-clinical-prevention-program-2\/clinical-prevention\/","title":{"rendered":"Clinical Prevention"},"content":{"rendered":"\n

\n\t\tClinical Prevention\n\t<\/h1>\n

\n\t\tSummary\n\t<\/h3>\n\tThis group’s area of study is the analysis of information associated with various diseases, in order to evaluate the approaches and propose alternatives to existing protocols on the treatment of smoking, international health and vaccine research, patient safety and nutrition, and chronic diseases.
\nThrough these studies and analyses, populations can be characterised (the level of vaccination, for example) and it is therefore possible to prevent potential health risks, as well as to analyse the effectiveness of preventive measures, and their impact on disease progression.\n

259<\/h2>\n

Publications<\/h2>\n\t\t\t\t\"grup_sense_foto_-_farmaco_4\"\n\t\t\t\t\tStrategic lines<\/a>\n\t\t\t\t\t\t\t\t\t\t\tExpand<\/i><\/a>\n\t\t\t\t\tTreatment of smoking
\nInternational health and vaccine research
\nPatient safety
\nNutrition and chronic diseases\n\t\t\t\t\tSelected Publications<\/a>\n\t\t\t\t\t\t\t\t\t\t\tExpand<\/i><\/a>\n\t\t\t\t\t

Ferrara,P;Ponticelli,D;Ag\u00fcero,F;Caci,G;Vitale,A;Borrelli,M;Schiavone,B et al, Does smoking have an impact on the immunological response to COVID-19 vaccines? Evidence from the VASCO study and need for further studies<\/strong>., Public Health, 2022;20397-99, doi:10.1016\/j.puhe.2021.12.013<\/p>\n

Antol\u00ed,A;Rocamora Blanch,G;Framil,M;Mas Bosch,V;Navarro,S;Bermudez,C;Martinez Yelamos,S et al, Evaluation of Humoral and Cellular Immune Responses to the SARS-CoV-2 Vaccine in Patients With Common Variable Immunodeficiency Phenotype and Patient Receiving B-Cell Depletion Therapy<\/strong>., Front. Immunol., 2022; 13895209-895209, doi:10.3389\/fimmu.2022.895209<\/p>\n

Pernin,V;Meneghini,M;Torija,A;Jouve,T;Del Bello,A;Sanz Mu\u00f1oz,I;Eiros,JM et al, Impaired antigen-specific B-cell responses after Influenza vaccination in kidney transplant recipients receiving co-stimulation blockade with Belatacept<\/strong>. Front. Immunol., 2022;13918887-918887, doi:10.3389\/fimmu.2022.918887<\/p>\n

D\u00edaz,NA;de Miguel,R;Ag\u00fcero,F;Sued,O;Arribas,JR;Ambrosioni,J;Hospital Clinic COVID 19 in HIV,I, Prevention and Treatment of SARS-CoV2 Infection in People Living with HIV: The Need for Specific Data<\/strong>., Infect. Dis. Ther., 2022;11(1):1-13, doi:10.1007\/s40121-021-00547-y<\/p>\n

Romero Pinel,L;Bau,L;Matas,E;Le\u00f3n,I;Mu\u00f1oz Vendrell,A;Arroyo,P;Masuet Aumatell,C et al, The age at onset of relapsing-remitting multiple sclerosis has increased over the last five decades<\/strong>., Mult. Scler. Relat. Disord., 2022;68104103-104103, doi:10.1016\/j.msard.2022.104103<\/p>\n\t\t\t\t\tSelected Projects<\/a>\n\t\t\t\t\t\t\t\t\t\t\tExpand<\/i><\/a>\n\t\t\t\t\t

2021-007-1. ESTUDIO DE FASE III, MULTINACIONAL, OBSERVADOR CIEGO, ALEATORIZADO, CONTROLADO CON PLACEBO PARA DEMOSTRAR LA EFICACIA DE UNA DOSIS \u00daNICA, AS\u00cd COMO DE DOSIS ANUALES DE REVACUNACI\u00d3N, DE LA VACUNA EN INVESTIGACI\u00d3N RSVPREF3 OA DE GSK EN ADULTOS DE 60 A\u00d1OS O M\u00c1S DE EDAD<\/strong>. Budget: 313840. 2021-2023. PI: RAMON TORRELL, JOSE MARIA.<\/p>\n

2022-037-1. Ensayo en fase 3, Aleatorizado, Doble-ciego, controlado con placebo para evaluar la Seguridad e Inmunogenicidad de la vacuna Ad26.RSV.preF en adultos de 18 a 59 a\u00f1os de edad, incluyendo aquellos con alto riesgo de VRS severo<\/strong>. Janssen-Cilag, S.A. Budget: 260000. 2022-2023. PI: Ramon Torrell, Josep Maria.<\/p>\n

19ACL084. ESTUDIO EPIDEMIOL\u00d3GICO PARA EVALUAR LA CARGA DE ENFERMEDAD DE LA INFECCI\u00d3N RESPIRATORIA AGUDA (IRA) ASOCIADA AL VIRUS RESPIRATORIO SINCITIAL (VRS) EN ADULTOS \u2265 50 A\u00d1OS DE EDAD DURANTE DOS TEMPORADAS CONSECUTIVAS DE VRS EN ESTADOS UNIDOS Y EUROPA<\/strong>. Budget: 199975. 2019-2022. PI: RAMON TORRELL, JOSE MARIA.<\/p>\n

2021-045-1. Estudio controlado de inmunogenia y seguridad de la vacuna candidata contra la fiebre amarilla (vYF) en investigaci\u00f3n en comparaci\u00f3n con Stamaril\u00ae<\/strong>. Sanofi-Aventis, S.A. Budget: 83759. 2021-2022. PI: Masuet i Aumatell, Cristina.<\/p>\n

20ACL174. Estudio fase I (primera vez en humanos), multic\u00e9ntrico, aleatorizado, simple ciego y de escalado controlado de dosis para evaluar la reactogenicidad, la seguridad, la inmunogenicidad y la eficacia de las vacunas frente al VHB basadas en vectores virales de GSK Biologicals administradas en una pauta de primovacunaci\u00f3n – refuerzo, con administraci\u00f3n secuencial o conjunta de una vacuna terap\u00e9utica de prote\u00ednas adyuvada (GSK3528869A), en pacientes con hepatitis B cr\u00f3nica (18 a 65 a\u00f1os) en tratamiento con an\u00e1logos de nucle\u00f3tidos (AN). T\u00edtulo anterior: Estudio para evaluar la seguridad, eficacia e inmunogenicidad de vacunas frente al VHB basadas en vectores virales y adyuvada de GSK BIOLOGICALS (GSK3528869A) en pacientes adultos con Hepatitis B Cr\u00f3nica<\/strong>. Budget: 83335. 2020- . PI: Masuet i Aumatell, Cristina.<\/p>\n\t\t\t\t\"Ramon\n

\n\t\tRamon Torrell, Josep M.\n\t<\/h4>\n

\n\t\t\n\t\tjmramon@idibell.cat\n\t\t<\/a>\n\t<\/h4>\n

\n\t\tPrincipal investigators\n\t<\/h2>\n\t\t\t\t\"Ramon\n

\n\t\tRamon Torrell, Josep M.\n\t<\/h4>\n

\n\t\t\n\t\tjmramon@idibell.cat\n\t\t<\/a>\n\t<\/h4>\n\t\t\t\t\"Cristina-Masuet-Aumatell\"\n

\n\t\tMasuet Aumatell, Cristina\n\t<\/h4>\n

\n\t\t\n\t\tcmasuet@idibell.cat\n\t\t<\/a>\n\t<\/h4>\n

\n\t\tTeam\n\t<\/h2>\n\t\t\t\t\t\t\t\t\t\t\t\tGroup leaders\t\t\t\t<\/a>\n\t\t\t\t\t\t\t\t\t\t\t\tPrincipal investigators\t\t\t\t<\/a>\n\t\t\t\t\t\t\t\t\t\t\t\tClinical researchers\t\t\t\t<\/a>\n\t\t\t\t\t\t\t\t\t\t\t\tScientific support\t\t\t\t<\/a>\n\t\t\t\t\t\t\t\t\t\t\t\tExternal collaborator\t\t\t\t<\/a>\n\t\t\t\t\t\tGroup leaders\n\t\t\t\t\t\t\t\t\t\t\t
    \n
  • Ramon Torrell, Josep M.<\/li>\n<\/ul>\n\t\t\t\t\t\tPrincipal investigators\n\t\t\t\t\t\t\t\t\t\t\t
      \n
    • Masuet Aumatell, Cristina<\/li>\n<\/ul>\n\t\t\t\t\t\tClinical researchers\n\t\t\t\t\t\t\t\t\t\t\t
        \n
      • Morchon, Sergi<\/li>\n
      • Ag\u00fcero Santangelo, Fernando<\/li>\n<\/ul>\n\t\t\t\t\t\tScientific support\n\t\t\t\t\t\t\t\t\t\t\t
          \n
        • Marchante Andujar, Jesus<\/li>\n<\/ul>\n\t\t\t\t\t\tExternal collaborator\n\t\t\t\t\t\t\t\t\t\t\t
            \n
          • Vega Ulloa, Elizabeth<\/li>\n<\/ul>\n

            \n\t\tRelated News\n\t<\/h2>\n\t\t

            Sorry, we couldn’t find any posts. Please try a different search.<\/p>\n\t\t\t\t

            \n\t